In a major milestone for neurodiagnostic technology, the United States Patent and Trademark Office recently issued Patent No. 12,642,479 for a groundbreaking “System for treating seizures and abnormal brain function.” Developed by a visionary team of inventors including Stéphane Bibian, Tatjana Zikov, and Mo Modarres, this cutting-edge system has been officially assigned to NeuroWave Systems Inc., an innovative medical device manufacturer based in Beachwood, Ohio. The patent details a sophisticated method for monitoring, analyzing, and treating abnormal cortical activity, representing a significant leap forward in neurological patient care.

This medical breakthrough comes at a pivotal moment as the healthcare industry shifts toward automated, real-time clinical solutions. By capturing and decoding complex electroencephalogram signals with unprecedented speed, the newly patented architecture bridges the critical gap between detection and clinical intervention. The announcement underscores the expanding influence of advanced signal processing in modern clinical settings, establishing a new benchmark for how neurological emergencies are managed in hospitals and critical care units worldwide.

Unrivaled Innovation in Seizure Mitigation

The core innovation of this system lies in its ability to perform real-time, instantaneous analysis of brain waves to detect and predict epileptic seizures or other forms of brain dysfunction. Traditional monitoring devices often suffer from significant processing delays or high false-positive rates, which can hinder timely medical intervention. NeuroWave’s patented technology utilizes advanced, wavelet-based signal processing algorithms to eliminate these tracking delays, providing medical professionals with immediate visibility into a patient’s neurological state. Furthermore, the system establishes a robust foundation for closed-loop therapeutic interventions, enabling automated drug delivery or targeted electrical stimulation to mitigate abnormal brain activity before clinical symptoms even manifest.

Ohio State Patent of the Month: July 2026

Thanks to its profound clinical implications and technical sophistication, this invention has been awarded the prestigious Patent of the Month in the state of Ohio for July 2026. This honor celebrates NeuroWave Systems Inc. as a beacon of regional innovation and emphasizes Ohio’s growing prominence as a major national hub for biomedical engineering and biotechnology. The selection committee highlighted how the system solves a long-standing challenge in critical care by replacing passive monitoring with active, rapid-response diagnostics. By originating this world-class medical asset within the state, the company has significantly boosted Ohio’s competitive edge in the global life sciences sector.

U.S. R&D Tax Credit Eligibility and Practical Applications

From a commercial and financial perspective, the practical applications of developing this patented system provide a classic framework for claiming the U.S. Research and Development (R&D) Tax Credit under Section 41. To qualify, a company’s activities must satisfy a rigorous four-part test requiring a permitted purpose, the elimination of technological uncertainty, a process of experimentation, and a reliance on hard sciences. The extensive engineering required to build this system, such as refining the wavelet-processing software algorithms, designing custom low-noise electronic circuits, and building the closed-loop feedback mechanisms, directly fits these criteria. Companies engaging in the design, prototyping, software coding, and clinical simulation testing of such neurodiagnostic platforms can identify these steps as Qualified Research Activities (QRAs). Consequently, the associated expenditures, including the wages of software developers, mechanical engineers, and clinical researchers, as well as supply costs and third-party contractor fees, can be leveraged to secure substantial tax credits to offset federal liabilities and fuel further innovation.